Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WH4P
|
|||
| Drug Name |
ENASIDENIB MESYLATE
|
|||
| Synonyms |
UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541
Click to Show/Hide
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Approved | [1] | |
| Company |
Celgene/Agios
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H21F6N7O4S
|
|||
| Canonical SMILES |
CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O.CS(=O)(=O)O
|
|||
| InChI |
1S/C19H17F6N7O.CH4O3S/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25;1-5(2,3)4/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32);1H3,(H,2,3,4)
|
|||
| InChIKey |
ORZHZQZYWXEDDL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1650550-25-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Isocitrate dehydrogenase (IDH) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Citrate cycle (TCA cycle) | |||
| Glutathione metabolism | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Carbon metabolism | ||||
| 2-Oxocarboxylic acid metabolism | ||||
| Biosynthesis of amino acids | ||||
| Peroxisome | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| WikiPathways | TCA Cycle | |||
| The citric acid (TCA) cycle and respiratory electron transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.